OTCMKTS:RCDTF Recordati Industria Chimica e Farmaceutica (RCDTF) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free RCDTF Stock Alerts $51.60 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$51.60▼$51.6050-Day Range$51.60▼$51.6052-Week Range$51.60▼$51.98VolumeN/AAverage Volume1 shsMarket CapitalizationN/AP/E Ratio26.74Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Get Recordati Industria Chimica e Farmaceutica alerts: Email Address Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Recordati Industria Chimica e Farmaceutica Stock (OTCMKTS:RCDTF)Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.Read More RCDTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCDTF Stock News HeadlinesMay 18 at 2:09 AM | americanbankingnews.comRecordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month Low at $51.60May 8, 2024 | markets.businessinsider.comHere's what to expect from Recordati Industria Chimica e Farmaceutica SPAAz Post raggruppamento's earningsApril 24, 2024 | msn.comBorsa: Milano fiacca con Recordati e Saipem, vola StmApril 23, 2024 | msn.comCVC explores options for Italy's Recordati, Bloomberg News reportsApril 23, 2024 | finance.yahoo.comCVC Explores Options for €11 Billion Drugmaker RecordatiApril 23, 2024 | finance.yahoo.comUPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reportsMarch 19, 2024 | msn.comFarmaceutica, le big si muovono: Astrazeneca acquista, Pfizer vende. Da Recordati cedola maggiorata con un occhio alle opportunitàDecember 29, 2023 | msn.comBorsa Milano, lieve rialzo (+0,07%), Recordati e banche in rialzoDecember 19, 2023 | seekingalpha.comRICFY Recordati Industria Chimica e Farmaceutica S.p.A.November 7, 2023 | msn.comItaly's Recordati sees 2023 results at top end of the rangeNovember 7, 2023 | uk.news.yahoo.comItaly's Recordati nudges up 2023 guidance as 9-mth revenue, profit jumpsSeptember 9, 2023 | forbes.comFondo pensione: cos’è e come funzionaJuly 21, 2023 | msn.comBorsa: Milano positiva con le banche, vola RecordatiMay 12, 2023 | msn.comItaly's Recordati boosted by strong sales in RussiaMay 11, 2023 | msn.comRecordati GAAP EPS of €0.59, revenue of €551.4MMay 11, 2023 | msn.comRecordati ups guidance on strong growth in specialty, primary care marketsApril 21, 2023 | msn.comRecordati, nel primo trimestre ricavi per 551,4 milioni di euro (+31,5%). Ok dei soci al buy back da massimi 200 milioniFebruary 21, 2023 | reuters.comRecordati shares fall after core profit margin forecasts disappointFebruary 17, 2023 | msn.comRecordati bocciata da Barclays. Che taglia il prezzo obiettivo da 40 a 35 euroJanuary 23, 2023 | reuters.comRECItah.MIJanuary 14, 2023 | businesswire.comCresce l'espansione di AESARA Europe con la nomina di Patrizia Berto, una veterana dell'industria farmaceutica italianaNovember 8, 2022 | msn.comRecordati alza la guidance per il 2022. Acconto del dividendo pari a 0,55 euroOctober 28, 2022 | finanznachrichten.deSherwin-Williams To Buy Italian Wood Coatings Firm Industria Chimica AdriaticaSeptember 27, 2022 | finance.yahoo.comRecordati Industria Chimica e Farmaceutica S.p.A. (0KBS.L)September 18, 2022 | finance.yahoo.comRecordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)See More Headlines Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica e Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CUSIPN/A CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,369Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.93 Trailing P/E Ratio26.74 Forward P/E Ratio18.36 P/E GrowthN/ANet Income$329.08 million Net Margins18.51% Pretax MarginN/A Return on Equity31.80% Return on Assets12.83% Debt Debt-to-Equity Ratio0.80 Current Ratio1.28 Quick Ratio0.86 Sales & Book Value Annual Sales$1.95 billion Price / SalesN/A Cash Flow$3.06 per share Price / Cash Flow16.86 Book Value$7.90 per share Price / Book6.53Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.32 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Robert Koremans M.D. (Age 62)CEO & Director Comp: $1.94MMr. Luigi Felice La Corte (Age 55)Group CFO & Executive Director Comp: $1.02MMs. Cathrin Petty (Age 51)Executive Director Mr. Giampiero Mazza (Age 55)Executive Director Mr. Giorgio De Palma (Age 50)Executive Director Ms. Eugenia LitzVP & Head of Investor RelationsMs. Bibianne BonGroup Chief Legal OfficerMs. Laura ContiGroup Communications DirectorMr. Gabriele FinziExecutive VP of Corporate Development, Licensing & InnovationMs. Alessandra AbateGroup Chief People & Culture OfficerMore ExecutivesKey CompetitorsAmplifonOTCMKTS:AMFPFbioMérieuxOTCMKTS:BMXMFDiaSorinOTCMKTS:DSRLFMDxHealthNASDAQ:MDXHPharma MarOTCMKTS:PHMMFView All Competitors RCDTF Stock Analysis - Frequently Asked Questions Should I buy or sell Recordati Industria Chimica e Farmaceutica stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Recordati Industria Chimica e Farmaceutica in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RCDTF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCDTF, but not buy additional shares or sell existing shares. View RCDTF analyst ratings or view top-rated stocks. How have RCDTF shares performed in 2024? Recordati Industria Chimica e Farmaceutica's stock was trading at $46.00 at the start of the year. Since then, RCDTF shares have increased by 12.2% and is now trading at $51.60. View the best growth stocks for 2024 here. How do I buy shares of Recordati Industria Chimica e Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RCDTF) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica e Farmaceutica S.p.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.